Anne H. Margulies - Jan 5, 2024 Form 4 Insider Report for SomaLogic, Inc. (SLGC)

Role
Director
Signature
/s/ Ruben Gutierrez, Attorney-in-Fact
Stock symbol
SLGC
Transactions as of
Jan 5, 2024
Transactions value $
$0
Form type
4
Date filed
1/9/2024, 09:40 PM
Previous filing
Mar 22, 2023
Next filing
Mar 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLGC Common Stock Disposed to Issuer -23.4K -100% 0 Jan 5, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLGC Stock Option (Right to buy) Disposed to Issuer -16.8K -100% 0 Jan 5, 2024 Common Stock 16.8K $4.77 Direct F3, F4
transaction SLGC Stock Option (Right to buy) Disposed to Issuer -33.5K -100% 0 Jan 5, 2024 Common Stock 33.5K $4.77 Direct F4, F5
transaction SLGC Stock Option (Right to buy) Disposed to Issuer -21K -100% 0 Jan 5, 2024 Common Stock 21K $4.77 Direct F3, F4
transaction SLGC Stock Option (Right to buy) Disposed to Issuer -46.7K -100% 0 Jan 5, 2024 Common Stock 46.7K $11.85 Direct F4, F6
transaction SLGC Stock Option (Right to buy) Disposed to Issuer -20.6K -100% 0 Jan 5, 2024 Common Stock 20.6K $9.08 Direct F3, F4
transaction SLGC Stock Option (Right to buy) Disposed to Issuer -20.6K -100% 0 Jan 5, 2024 Common Stock 20.6K $2.30 Direct F4, F7
transaction SLGC Restricted Stock Unit Disposed to Issuer -3.43K -100% 0 Jan 5, 2024 Common Stock 3.43K Direct F8, F9, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Anne H. Margulies is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger").
F2 (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock.
F3 The option is fully vested and exercisable.
F4 Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions.
F5 The option vested as to 1/4th of the total grant on May 12, 2021, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
F6 The option vested as to 1/4th of the total grant on October 27, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
F7 The option shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date.
F8 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration.
F9 The RSUs shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date.
F10 Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time.